A potential competition bias in the detection of safety signals from spontaneous reporting databases

To study whether reports related to known drug‐event associations could hinder the detection of new signals by increasing the detection thresholds when using disporportionality analyses in spontaneous reporting (SR) databases.

[1]  B. Bégaud,et al.  Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system , 1998, European Journal of Clinical Pharmacology.

[2]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[3]  P. Waller,et al.  Regulatory Pharmacovigilance in the United Kingdom: Current Principles and Practice , 1996, Pharmacoepidemiology and drug safety.

[4]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[5]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[6]  Richard Beasley,et al.  Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. , 2004, Clinical therapeutics.

[7]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[8]  R. Mann,et al.  Pharmacovigilance (2nd ed.) , 2007 .

[9]  A. Egberts,et al.  Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. , 2001, British journal of clinical pharmacology.

[10]  B. M. D. B. Stephens MB.  The Detection of New Adverse Drug Reactions , 1985, Palgrave Macmillan UK.

[11]  Frantz Thiessard,et al.  The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions , 2005, Pharmacoepidemiology and drug safety.

[12]  R. Royer,et al.  ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY , 1985, The Lancet.

[13]  Signal Detection in the Pharmaceutical Industry , 2007, Drug safety.

[14]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[15]  Alasdair Breckenridge,et al.  Meyler's Side Effects of Drugs , 1976 .

[16]  C. Foster,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  Frantz Thiessard,et al.  Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance , 2005, IEEE Transactions on Information Technology in Biomedicine.

[18]  Nicholas Moore,et al.  Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole , 2003, Pharmacoepidemiology and drug safety.

[19]  A. Pariente,et al.  Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias , 2007, Drug safety.

[20]  N. Moore,et al.  [French pharmacovigilance database system: examples of utilisation]. , 1995, Therapie.

[21]  F. Haramburu,et al.  Spontaneous reporting of adverse drug reactions: who reports and what? , 1998, Pharmacoepidemiology and drug safety.

[22]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[23]  W. DuMouchel,et al.  Comparative Performance of Two Quantitative Safety Signalling Methods , 2006, Drug safety.

[24]  F. Haramburu,et al.  Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. , 2003, British journal of clinical pharmacology.

[25]  A. Pariente,et al.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.

[26]  L. Hughes-Davies,et al.  Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.

[27]  Kenneth J Rothman,et al.  The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.

[28]  J. O’Donnell.  Detection of New Adverse Drug Reactions, 4th Edition , 1999 .

[29]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[30]  Effect of Date of Drug Marketing on Disproportionality Measures in Pharmacovigilance , 2009, Drug safety.

[31]  Bernard Bégaud,et al.  Rates of spontaneous reporting of adverse drug reactions in France. , 2002, JAMA.

[32]  A. Bate,et al.  Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs , 2002, European Journal of Clinical Pharmacology.

[33]  Leopold Meyler,et al.  Meyler's Side Effects of Drugs , 1992 .